-

01:30:35 PM

MYGN Stock News

MYGN - Myriad Genetics, Inc.

05/26/22 6:30 PM

Nasdaq : MYGN

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide

RHEA-AI

neutral

05/05/22 9:00 AM

Nasdaq : MYGN

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

Highlights: Revenue of $164.9 million for the quarter ended March 31, 2022 Excluding revenue from divested businesses, revenue increased 11% year-over-year D iluted GAAP earnings per share (EPS) of $(0.26) and adjusted EPS of $(0.03) in the first quarter of 2022 improved by $0.26 and $0.03

RHEA-AI

neutral

05/04/22 4:05 PM

Nasdaq : MYGN

conferences

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the company’s transformation and growth plan during a fireside chat at the Bank of America Securities

RHEA-AI

neutral

05/03/22 4:15 PM

Nasdaq : MYGN

partnership

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of

RHEA-AI

very positive

04/28/22 4:05 PM

Nasdaq : MYGN

earnings

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on Thursday, May 5, 2022 at 4:30 p.m. EDT. The company’s quarterly earnings will be released the

RHEA-AI

neutral

04/26/22 7:05 AM

Nasdaq : MYGN

2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment

Two out of three women diagnosed with depression or anxiety say

RHEA-AI

negative

03/14/22 7:05 AM

Nasdaq : MYGN

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine,

RHEA-AI

positive

03/11/22 7:05 PM

Nasdaq : MYGN

fda approval

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine,

RHEA-AI

positive

03/08/22 7:22 AM

Nasdaq : MYGN

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has been

RHEA-AI

very positive

03/02/22 4:30 PM

Nasdaq : MYGN

conferences

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in a fireside chat at the 42 nd Annual Cowen Health Care Conference on March 8, 2022 at 9:50 a.m.

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

MYGN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.myriad.com
CeoR. Bryan Riggsbee
Security nameMyriad Genetics, Inc.
Issue typecs
SectorManufacturing
Sic code2835
Employees2700
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address320 S Wakara Way
StateUtah
CitySalt Lake City
Zip84108-1214
CountryUS
Phone18015843600

About Myriad Genetics, Inc.

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.